Clinical Trial Update: BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating Brentuximab vedotin for relapsed/refractory Hodgkin lymphoma; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Xiuhua Sun | Conditions: Hodgkin Lymphoma (Category) | Phase 4 | Status: NOT_YET_RECRUITING